Search
引用和文献 (27)
Gibco™
CTS™ AIM V™ SFM
GIBCO™ CTS™ AIM V™ SFM（治疗级）是商业化的可用于 T 细胞和树突状细胞的增殖和/或控制的成分确定的无血清培养基 (SFM)，生产过程符合了解更多信息
Have Questions?
更改视图
| 货号 | 数量 |
|---|---|
| 0870112BK | 10 L |
| 0870112DK | 1000 mL |
货号 0870112BK
价格（CNY)
24,242.00
Each
数量:
10 L
价格（CNY)
24,242.00
Each
GIBCO™ CTS™ AIM V™ SFM（治疗级）是商业化的可用于 T 细胞和树突状细胞的增殖和/或控制的成分确定的无血清培养基 (SFM)，生产过程符合 cGMP 的标准规范。CTS™ AIM V™ SFM 被食品药品监督管理局 FDA 510(k) 批准认可，适用于人类离体组织和细胞培养处理应用。它含有 L-谷氨酰胺、50 μg/mL 硫酸链霉素和 10 μg/mL 硫酸庆大霉素。
适用于人类离体组织和细胞培养处理应用。注意：不可用于人类或动物直接给药。
适用于人类离体组织和细胞培养处理应用。注意：不可用于人类或动物直接给药。
用于研究或生产基于细胞、基因或者组织的产品。注意：不可直接作用于人类或动物给药。
规格
细胞类型单核细胞、树突状细胞、T 细胞、杂交瘤细胞、PBMC、成纤维细胞、巨噬细胞、骨髓瘤细胞、淋巴细胞
适用于（应用）细胞和基因治疗研究，开发和生产
产品规格BPC
生产质量ISO 13485、21 CFR 820
产品类型细胞培养基
数量10 L
有效期14 months from date of manufacture
运输条件Ambient
分类动物来源
形式液体
血清水平无血清
无菌无菌过滤
Unit SizeEach
内容与储存
储存条件：2-8°C。避光
运输条件：环境
有效期：自生产之日起18个月
运输条件：环境
有效期：自生产之日起18个月
常见问题解答 (FAQ)
Will CTS AIM V SFM (Cat. No. 0870112BK) be discontinued?
Where can I get more information about Aegis 5-14 BPC (BioProcessing Container)?
What type of film is currently used for packaging CTS AIM V SFM (Cat. No. 0870112BK)?
What is the difference between CTS AIM V SFM VALIDATION (Cat. No. A4000311302) and CTS AIM V SFM (Cat. No. 0870112BK)?
What is CTS?
引用和文献 (27)
引用和文献
Abstract
Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.
Journal:J Immunol
PubMed ID:17878372
'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause
[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]
Journal:Nippon Hinyokika Gakkai Zasshi
PubMed ID:8320888
'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily
Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway.
Journal:J Biol Chem
PubMed ID:11812790
'In tyrosinase-positive amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum. Based on studies described here, we propose that aberrant vacuolar proton ATPase (V-ATPase)-mediated proton transport in melanoma cells disrupts tyrosinase trafficking through the secretory pathway. Amelanotic but not melanotic melanoma cells or normal melanocytes display elevated proton export
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.
Journal:J Immunol Methods
PubMed ID:18242633
'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the